Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®

Completed enrollment of patient expansion cohort of 20 patients at the RP2D of 4 mg/kg in combination with KEYTRUDA® (pembrolizumab) in first line...

Related Keywords

Boston ,Massachusetts ,United States ,Maya Romanchuck ,Matteo Levisetti ,Marie Campinell ,Daniel Passeri ,Corporate Communications ,Securities Exchange ,Cue Biopharma Inc ,Society For Immunotherapy Of Cancer ,Nasdaq ,Drug Administration ,Lifesci Communications ,Twitter ,Neck Cancer ,Annual Meeting ,Fast Track Designation ,Cue Biopharma ,Wilm Tumor ,Selective Targeting ,Securities Act ,Securities Exchange Act ,Risk Factors ,Financial Condition ,Annual Report ,Quarterly Report ,